This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
CLL Society Address! Please note that the new address for sending donations and correspondence to CLL Society is PO Box 3197, Olathe, KS, 66063. Headquarters for the CLL Society remain in Claremont, CA but the Claremont, CA PO Box is no longer active.
Speaking of deposits: The CLL Society can accept your donations of cash, stocks, vehicles, and many other gifts, then transform your generosity into programs and services to educate all CLL patients to advocate for the best possible care for their CLL. Smart Patients Get Smart Care™. Find out more here.
And speaking of Smart Care: We are celebrating 10 Years of Covering ASH (and all the other major hematology conferences) with our 10 Years/ 10 Bucks (or ten $10s or ten $100s or whatever you can give) Campaign! 10 years ago, there was no treatment, short of a successful bone marrow transplant, shown to prolong life after diagnosis with CLL. 10 years ago, a college kid with a camera (Ben), a devastated wife (Patty), and a physician with an incurable disease (Brian) were pushed to the limit, but they had a great idea: Show up at ASH 2011 and report what they learned. That took guts. ASH 2011 resulted in Brian meeting Dr. John Byrd, who “penciled him in” to one of the last available spots in a clinical trial for PCI-32765. PCI-32765 became ibrutinib. It saved Brian’s life. That great idea to report the latest research from the investigators themselves, became the CLL Society! 10 years later, the CLL Society with its programs, services and 35-member Medical Advisory Board still keeps you in the know! Celebrate with us!
During ASH 2019, our own Dr. Brian Koffman interviewed Dr. Paul Barr, Associate Professor of Medicine at the Wilmot Cancer Institute, in Rochester, NY, where they discussed a new analysis of clinical trial data that looks at how effective ibrutinib is depending on when it is used in a patient’s course of therapy. Is the best time to use it early on in treatment? Or should it be used after other treatment options have failed? A post-hoc analysis of the RESONATE and RESONATE 2 studies were used. Watch the interview here.
Get silly with us!
Normally we’re serious around here, as we are laser-focused on meeting the unmet needs of CLL patients and intent upon pursuing the annihilation of all of the challenges that CLL brings. Sometimes we’re silly! You get both in this casual tête-à-tête I had with Dr. John Byrd when I asked him for his “wish list” at the close of ASH 2019. Dr. Byrd touches on topics you would expect, such as BTK Inhibitors, fixed duration therapies, the hope that ARQ531 might relieve Richter’s transformation, and last but not least, survivorship issues. Let’s have some perspective here. CLL treatments are better than ever. CLL patients are living longer than ever, many with little or no CLL interference in their daily lives. However, it can be hard to let down our guard and cast away the tendency to define ourselves as ill when CLL is given a back seat. So, let’s worry about some really important things here! Is your CLL-surviving spouse washing the dishes? Is he/ she mowing the lawn? Get silly with us! Watch the interview here.
Join us on December 4, with Dr. John Gribben and panelists for a CLL Society and PeerView joint-sponsored pre-ASH 2020 event! An expert panel will present practice-changing evidence for the treatment of CLL with novel therapeutics and explore real-world patient case scenarios. Our broadcast will also feature perspectives on the patient’s experience of CLL therapy. Register here for this exciting activity to learn about important management updates and patient perspectives on the treatment of CLL.
Two Instant Replays!
Replay #1 We saved it for you! On Nov. 17, Dr. Joe Fraietta brought us his beautiful slide set, the authority of his long research and clinical experience, and his unbounded enthusiasm for moving CAR-T science forward in a content-rich CLL Society Webinar “The Future of CAR-T Therapy: Can CAR-T Cure CLL?”Moderated by Dr. Brian Koffman, enlivened with our audience’s questions, and sparkling with projections about the future of CAR-T! Couldn’t make it? No worries. We’ve saved you a seat at the replay!
Huntsman Virtual Patient Education Forum
Replay #2 We saved this for you, too! CLL Society Virtual Patient & Caregiver Educational Forum with Dr. Deborah Stephens at Huntsman Cancer Institute on November 14 was a great learning experience for all. In both her research and her clinical practice, Dr. Stephens is known to be particularly sensitive to the issues that are of importance to patients during their CLL journey. Our Instant Replay of Dr. Stephens and her team at Huntsman, partnering with CLL Society again this year to host a well-rounded joint effort to cover the basics of CLL diagnosis, early management, clinical trials, treatment options and patient perspectives is only a click away; watch here!
Dr. Susan O’Brien is Honored
Dr. Susan M. O’Brien, the UCI Chao Family Comprehensive Cancer Center’s Associate Director for Clinical Research, has been named a Giant of Cancer Care® for her sustained contributions in the field of leukemia. Dr. O’Brien’s decades of research and clinical care have dramatically improved the lives of so many CLL patients. She is richly deserving of being recognized as a Giant of Cancer Care. We share the details of her award here.
Please support the CLL Society, the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
Thank you and stay safe!
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.